Identification of a secondary promoter of CASP8 and its related transcription factor PURα

Lin,Zhengwei; Guo,Zhimin; Xu,Yang; Zhao,Xiaohang

doi:10.3892/ijo.2014.2436

Identification of a secondary promoter of CASP8 and its related transcription factor PURα

Authors:
- Zhengwei Lin
- Zhimin Guo
- Yang Xu
- Xiaohang Zhao
View Affiliations

Affiliations: State Key Laboratory of Molecular Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China
Published online on: May 9, 2014 https://doi.org/10.3892/ijo.2014.2436
Pages: 57-66
Copyright: © Lin et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Caspase-8 (CASP8) is an essential initiator of apoptosis and is associated with many diseases in humans including esophageal squamous cell carcinoma. CASP8 produces a variety of transcripts, which might perform distinct functions. However, the cis and trans transcriptional determinants that control CASP8 expression remain poorly defined. Using a series of luciferase reporter assays, we identified a novel secondary promoter of CASP8 within chr2: 202,122,236 to 202,123,227 and 25 kb downstream of the previously described CASP8 promoter. ENCODE ChIP-seq data for this novel promoter region revealed several epigenetic features, including high levels of histone H3 lysine 27 acetylation and lysine 4 methylation, as well as low levels of CpG island methylation. We developed a mass spectrometry based strategy to identify transcription factors that contribute to the function of the secondary promoter. We found that the transcription activator protein PURα is specifically involved in the transcriptional activation of the secondary promoter and may exert its function by forming a complex with E2F-1 and RNA polymerase II. PURα can bind to both DNA and RNA, and functions in the initiation of DNA replication, regulation of transcription. We observed that knockdown of PURα expression decreased the transcriptional activity of the secondary promoter and mRNA expression of CASP8 isoform G. Although the physiologic roles of this secondary promoter remain unclear, our data may help explain the complexity of CASP8 transcription and suggest that the various caspase 8 isoforms may have distinct regulations and functions.

View Figures

View References

1.	Shi Y: Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell. 9:459–470. 2002. View Article : Google Scholar : PubMed/NCBI
2.	Raff M: Cell suicide for beginners. Nature. 396:119–122. 1998. View Article : Google Scholar : PubMed/NCBI
3.	Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science. 267:1456–1462. 1995. View Article : Google Scholar : PubMed/NCBI
4.	Hengartner MO: The biochemistry of apoptosis. Nature. 407:770–776. 2000. View Article : Google Scholar : PubMed/NCBI
5.	Li H, Zhu H, Xu CJ and Yuan J: Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 94:491–501. 1998. View Article : Google Scholar : PubMed/NCBI
6.	Varfolomeev EE, Schuchmann M, Luria V, et al: Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity. 9:267–276. 1998. View Article : Google Scholar : PubMed/NCBI
7.	Kang TB, Ben-Moshe T, Varfolomeev EE, et al: Caspase-8 serves both apoptotic and nonapoptotic roles. J Immunol. 173:2976–2984. 2004. View Article : Google Scholar : PubMed/NCBI
8.	Kang TB, Oh GS, Scandella E, et al: Mutation of a self-processing site in caspase-8 compromises its apoptotic but not its nonapoptotic functions in bacterial artificial chromosometransgenic mice. J Immunol. 181:2522–2532. 2008. View Article : Google Scholar : PubMed/NCBI
9.	Sakamaki K, Inoue T, Asano M, et al: Ex vivo whole-embryo culture of caspase-8-deficient embryos normalize their aberrant phenotypes in the developing neural tube and heart. Cell Death Differ. 9:1196–1206. 2002. View Article : Google Scholar
10.	Galluzzi L, Kepp O and Kroemer G: RIP kinases initiate programmed necrosis. J Mol Cell Biol. 1:8–10. 2009. View Article : Google Scholar
11.	Boldin MP, Goncharov TM, Goltsev YV and Wallach D: Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell. 85:803–815. 1996. View Article : Google Scholar
12.	Scaffidi C, Medema JP, Krammer PH and Peter ME: FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b. J Biol Chem. 272:26953–26958. 1997. View Article : Google Scholar : PubMed/NCBI
13.	Horiuchi T, Himeji D, Tsukamoto H, Harashima S, Hashimura C and Hayashi K: Dominant expression of a novel splice variant of caspase-8 in human peripheral blood lymphocytes. Biochem Biophys Res Commun. 272:877–881. 2000. View Article : Google Scholar : PubMed/NCBI
14.	Himeji D, Horiuchi T, Tsukamoto H, Hayashi K, Watanabe T and Harada M: Characterization of caspase-8L: a novel isoform of caspase-8 that behaves as an inhibitor of the caspase cascade. Blood. 99:4070–4078. 2002. View Article : Google Scholar : PubMed/NCBI
15.	Miller MA, Karacay B, Zhu X, O’Dorisio MS and Sandler AD: Caspase 8L, a novel inhibitory isoform of caspase 8, is associated with undifferentiated neuroblastoma. Apoptosis. 11:15–24. 2006. View Article : Google Scholar : PubMed/NCBI
16.	Mohr A, Zwacka RM, Jarmy G, et al: Caspase-8L expression protects CD34⁺hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis. Oncogene. 24:2421–2429. 2005.PubMed/NCBI
17.	Casciano I, De Ambrosis A, Croce M, et al: Expression of the caspase-8 gene in neuroblastoma cells is regulated through an essential interferon-sensitive response element (ISRE). Cell Death Differ. 11:131–134. 2004. View Article : Google Scholar : PubMed/NCBI
18.	Casciano I, Banelli B, Croce M, et al: Caspase-8 gene expression in neuroblastoma. Ann NY Acad Sci. 1028:157–167. 2004. View Article : Google Scholar : PubMed/NCBI
19.	Teitz T, Wei T, Valentine MB, et al: Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med. 6:529–535. 2000. View Article : Google Scholar : PubMed/NCBI
20.	Kim HS, Lee JW, Soung YH, et al: Inactivating mutations of caspase-8 gene in colorectal carcinomas. Gastroenterology. 125:708–715. 2003. View Article : Google Scholar : PubMed/NCBI
21.	Mandruzzato S, Brasseur F, Andry G, Boon T and van der Bruggen P: A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med. 186:785–793. 1997. View Article : Google Scholar : PubMed/NCBI
22.	Soung YH, Lee JW, Kim SY, et al: CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas. Cancer Res. 65:815–821. 2005.PubMed/NCBI
23.	Takita J, Yang HW, Chen YY, et al: Allelic imbalance on chromosome 2q and alterations of the caspase 8 gene in neuroblastoma. Oncogene. 20:4424–4432. 2001. View Article : Google Scholar : PubMed/NCBI
24.	Hopkins-Donaldson S, Ziegler A, Kurtz S, et al: Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ. 10:356–364. 2003. View Article : Google Scholar : PubMed/NCBI
25.	Abnet CC, Wang Z, Song X, et al: Genotypic variants at 2q33 and risk of esophageal squamous cell carcinoma in China: a meta-analysis of genome-wide association studies. Hum Mol Genet. 21:2132–2141. 2012. View Article : Google Scholar : PubMed/NCBI
26.	Maher B: ENCODE: The human encyclopaedia. Nature. 489:46–48. 2012. View Article : Google Scholar
27.	Vaillant I and Paszkowski J: Role of histone and DNA methylation in gene regulation. Curr Opin Plant Biol. 10:528–533. 2007. View Article : Google Scholar : PubMed/NCBI
28.	Darbinian N, White MK, Gallia GL, Amini S, Rappaport J and Khalili K: Interaction between the pura and E2F-1 transcription factors. Anticancer Res. 24:2585–2594. 2004.PubMed/NCBI
29.	Kadonaga JT: Regulation of RNA polymerase II transcription by sequence-specific DNA binding factors. Cell. 116:247–257. 2004. View Article : Google Scholar : PubMed/NCBI
30.	Oei SL, Griesenbeck J, Schweiger M and Ziegler M: Regulation of RNA polymerase II-dependent transcription by poly(ADP-ribosyl)ation of transcription factors. J Biol Chem. 273:31644–31647. 1998. View Article : Google Scholar : PubMed/NCBI
31.	Coulon A, Chow CC, Singer RH and Larson DR: Eukaryotic transcriptional dynamics: from single molecules to cell populations. Nat Rev Genet. 14:572–584. 2013. View Article : Google Scholar : PubMed/NCBI
32.	Lenhard B, Sandelin A and Carninci P: Metazoan promoters: emerging characteristics and insights into transcriptional regulation. Nat Rev Genet. 13:233–245. 2012.PubMed/NCBI
33.	Kornblihtt AR, Schor IE, Allo M, Dujardin G, Petrillo E and Munoz MJ: Alternative splicing: a pivotal step between eukaryotic transcription and translation. Nat Rev Mol Cell Biol. 14:153–165. 2013. View Article : Google Scholar : PubMed/NCBI
34.	Ayoubi TA and Van De Ven WJ: Regulation of gene expression by alternative promoters. FASEB J. 10:453–460. 1996.PubMed/NCBI
35.	Landry JR, Mager DL and Wilhelm BT: Complex controls: the role of alternative promoters in mammalian genomes. Trends Genet. 19:640–648. 2003. View Article : Google Scholar : PubMed/NCBI
36.	Carninci P, Kasukawa T, Katayama S, et al: The transcriptional landscape of the mammalian genome. Science. 309:1559–1563. 2005. View Article : Google Scholar : PubMed/NCBI
37.	Katayama S, Tomaru Y, Kasukawa T, et al: Antisense transcription in the mammalian transcriptome. Science. 309:1564–1566. 2005. View Article : Google Scholar : PubMed/NCBI
38.	Carninci P, Sandelin A, Lenhard B, et al: Genome-wide analysis of mammalian promoter architecture and evolution. Nat Genet. 38:626–635. 2006. View Article : Google Scholar : PubMed/NCBI
39.	Yoo EJ, Cooke NE and Liebhaber SA: Identification of a secondary promoter within the human B cell receptor component gene hCD79b. J Biol Chem. 288:18353–18365. 2013. View Article : Google Scholar : PubMed/NCBI
40.	Laszkiewicz A, Cebrat M, Miazek A and Kisielow P: Complexity of transcriptional regulation within the Rag locus: identification of a second Nwc promoter region within the Rag2 intron. Immunogenetics. 63:183–187. 2011. View Article : Google Scholar : PubMed/NCBI
41.	Pinte S, Guerardel C, Deltour-Balerdi S, Godwin AK and Leprince D: Identification of a second G-C-rich promoter conserved in the human, murine and rat tumor suppressor genes HIC1. Oncogene. 23:4023–4031. 2004. View Article : Google Scholar : PubMed/NCBI
42.	Rini D and Calabi F: Identification and comparative analysis of a second runx3 promoter. Gene. 273:13–22. 2001. View Article : Google Scholar : PubMed/NCBI
43.	Burton EA, Tinsley JM, Holzfeind PJ, Rodrigues NR and Davies KE: A second promoter provides an alternative target for therapeutic up-regulation of utrophin in Duchenne muscular dystrophy. Proc Natl Acad Sci USA. 96:14025–14030. 1999. View Article : Google Scholar : PubMed/NCBI
44.	Sun T, Gao Y, Tan W, et al: A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet. 39:605–613. 2007. View Article : Google Scholar : PubMed/NCBI
45.	Haiman CA, Garcia RR, Kolonel LN, Henderson BE, Wu AH and Le Marchand L: A promoter polymorphism in the CASP8 gene is not associated with cancer risk. Nat Genet. 40:259–260. 2008. View Article : Google Scholar : PubMed/NCBI
46.	Frank B, Rigas SH, Bermejo JL, et al: The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study. Breast Cancer Res Treat. 111:139–144. 2008. View Article : Google Scholar : PubMed/NCBI
47.	Cybulski C, Wokolorczyk D, Gliniewicz B, et al: A six-nucleotide deletion in the CASP8 promoter is not associated with a susceptibility to breast and prostate cancers in the Polish population. Breast Cancer Res Treat. 112:367–368. 2008. View Article : Google Scholar : PubMed/NCBI
48.	Pittman AM, Broderick P, Sullivan K, et al: CASP8 variants D302H and -652 6N ins/del do not influence the risk of colorectal cancer in the United Kingdom population. Br J Cancer. 98:1434–1436. 2008. View Article : Google Scholar : PubMed/NCBI
49.	Xiao MS, Chang L, Li WL, et al: Genetic polymorphisms of the CASP8 gene promoter may not be associated with colorectal cancer in Han Chinese from Southwest China. PLoS One. 8:e675772013. View Article : Google Scholar : PubMed/NCBI
50.	de Martino M, Haitel A, Schatzl G, Klingler HC and Klatte T: The CASP8 -652 6N insertion/deletion promoter polymorphism is associated with renal cell carcinoma risk and metastasis. J Urol. 190:717–722. 2013.PubMed/NCBI
51.	Malik MA, Zargar SA and Mittal B: A six-nucleotide deletion polymorphism in the casp8 promoter is associated with reduced risk of esophageal and gastric cancers in Kashmir valley. Indian J Hum Genet. 17:152–156. 2011. View Article : Google Scholar
52.	Li C, Lu J, Liu Z, et al: The six-nucleotide deletion/insertion variant in the CASP8 promoter region is inversely associated with risk of squamous cell carcinoma of the head and neck. Cancer Prev Res. 3:246–253. 2010. View Article : Google Scholar : PubMed/NCBI
53.	Wang M and Zhang Z, Tian Y, Shao J and Zhang Z: A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter associated with risk and progression of bladder cancer. Clin Cancer Res. 15:2567–2572. 2009. View Article : Google Scholar : PubMed/NCBI
54.	Ni C, Ye Y, Wang M, et al: A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with risk of coal workers’ pneumoconiosis. J Toxicol Environ Health A. 72:712–716. 2009.PubMed/NCBI
55.	Qu H and Fang X: A brief review on the Human Encyclopedia of DNA Elements (ENCODE) project. Genomics Proteomics Bioinformatics. 11:135–141. 2013. View Article : Google Scholar
56.	Gerstein MB, Kundaje A, Hariharan M, et al: Architecture of the human regulatory network derived from ENCODE data. Nature. 489:91–100. 2012. View Article : Google Scholar : PubMed/NCBI
57.	Bajic VB, Brent MR, Brown RH, et al: Performance assessment of promoter predictions on ENCODE regions in the EGASP experiment. Genome Biol. 7(Suppl 1): S31–13. 2006. View Article : Google Scholar : PubMed/NCBI
58.	Bardet AF, Steinmann J, Bafna S, Knoblich JA, Zeitlinger J and Stark A: Identification of transcription factor binding sites from ChIP-seq data at high resolution. Bioinformatics. 29:2705–2713. 2013. View Article : Google Scholar : PubMed/NCBI
59.	Johnson EM: The Pur protein family: clues to function from recent studies on cancer and AIDS. Anticancer Res. 23:2093–2100. 2003.PubMed/NCBI
60.	Johnson EM, Daniel DC and Gordon J: The pur protein family: genetic and structural features in development and disease. J Cell Physiol. 228:930–937. 2013. View Article : Google Scholar : PubMed/NCBI
61.	Darbinian N, Gallia GL and Khalili K: Helix-destabilizing properties of the human single-stranded DNA- and RNA-binding protein Puralpha. J Cell Biochem. 80:589–595. 2001. View Article : Google Scholar : PubMed/NCBI
62.	Algeciras-Schimnich A, Barnhart BC and Peter ME: Apoptosis-independent functions of killer caspases. Curr Opin Cell Biol. 14:721–726. 2002. View Article : Google Scholar : PubMed/NCBI
63.	Launay S, Hermine O, Fontenay M, Kroemer G, Solary E and Garrido C: Vital functions for lethal caspases. Oncogene. 24:5137–5148. 2005. View Article : Google Scholar : PubMed/NCBI
64.	Knudsen S: Promoter2.0: for the recognition of PolII promoter sequences. Bioinformatics. 15:356–361. 1999. View Article : Google Scholar : PubMed/NCBI
65.	Reese MG: Application of a time-delay neural network to promoter annotation in the Drosophila melanogaster genome. Comput Chem. 26:51–56. 2001. View Article : Google Scholar
66.	Solovyev V and Salamov A: The Gene-Finder computer tools for analysis of human and model organisms genome sequences. Proc Int Conf Intell Syst Mol Biol. 5:294–302. 1997.PubMed/NCBI